CTOs on the Move

Affitech USA

www.affitech.com

 
Affitech USA is a Walnut Creek, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.affitech.com
  • 1945 Arbol Grande
    Walnut Creek, CA USA 94595
  • Phone: 925.935.9803

Executives

Name Title Contact Details

Similar Companies

SomnoMedics

SomnoMedics, LLC is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Abgent

Abgent is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BrainScope

BrainScope is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthego

Synthego is a leading provider of genome engineering solutions. Our flagship product, CRISPRevolution, is a portfolio of synthetic guide RNA designed for CRISPR genome editing and research. Synthego`s vision is to bring precision and automation to genome engineering, enabling rapid and cost-effective research with consistent results for every scientist.

Provention Bio

Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases. -We seek technologies or targets designed to predict, preempt or intervene before immune disease begins, re-appears or progresses. -We are creating a new biopharmaceutical category for autoimmunity. We leverage a transformational drug development strategy that sources, repositions and advances candidates that: -Target the interception or prevention of immune-mediated disease -Have been underdeveloped or deprioritized because of insufficient clinical trial efficacy or for strategic reasons -Have demonstrated proof-of-mechanism by preventing or intercepting immunopathologic pathways We believe that our deep understanding of immune-mediated pathophysiology, experience in translational medicine, and expertise in the design of rapid go/no-go clinical trials enables us to identify and evaluate potential therapeutic candidates for acquisition or in-licensing.